AlanylglutamineAlternative Names: (D-Glu)-isomer-alanylglutamine; Ala-Gln; Alanyl-glutamine; Dipeptiven; N(2)-L-alanyl-L-glutamine; PD-Protec
Latest Information Update: 22 Jul 2016
At a glance
- Originator Zytoprotec
- Class Cytoprotectives; Dipeptides
- Mechanism of Action Immunosuppressants; Interleukin 8 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Peritonitis
Most Recent Events
- 21 Jul 2016 Alanylglutamine is still in phase II trials for Peritonitis (prevention, in patients with chronic renal failure) in Austria (EudraCT2013-000400-42)
- 13 May 2014 Phase-II clinical trials in Peritonitis (prevention, in patients with chronic renal failure) in Austria (IV)